Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8IZN3
UPID:
ZDH14_HUMAN
Alternative names:
DHHC domain-containing cysteine-rich protein 14; NEW1 domain-containing protein; Zinc finger DHHC domain-containing protein 14
Alternative UPACC:
Q8IZN3; A6NDB7; Q5JS07; Q5JS08; Q6PHS4; Q8IZN2; Q9H7F1
Background:
Palmitoyltransferase ZDHHC14, also known as DHHC domain-containing cysteine-rich protein 14, plays a crucial role in cellular processes by catalyzing the addition of palmitate onto various protein substrates. Its activity towards the beta-2 adrenergic receptor (ADRB2) is significant for regulating G protein-coupled receptor signaling, impacting cell differentiation and apoptosis.
Therapeutic significance:
Understanding the role of Palmitoyltransferase ZDHHC14 could open doors to potential therapeutic strategies.